In in vivo models using the AD transgenic C. elegans strains CL4176 and BR5270, CAP effectively alleviates the motor dysfunction caused by tau protein aggregation, reduces paralysis and hypersensitivity to 5-HT caused by Aβ, and decreases Aβ deposition. The gene discussed is MAPT; the disease is Alzheimer disease.